Ono Pharmaceutical Co Ltd represents values of innovation, integrity, and commitment to improving human health. Their corporate philosophy focuses on putting patients first and striving for excellence in research and development. Ono Pharmaceutical aims to contribute to society by developing innovative medicines and therapeutic solutions. With a strong emphasis on compliance and ethical standards, the company actively engages in collaborations and partnerships to accelerate the discovery and development of novel therapies. Through their dedication to advancing healthcare and delivering value to stakeholders, Ono Pharmaceutical Co Ltd has established itself as a leading player in the pharmaceutical industry.

Ono Pharmaceutical Co Ltd is primarily present in Japan.

Ono Pharmaceutical Co Ltd has achieved several significant milestones. Notably, they received approval for Opdivo, an anti-cancer medication, from the U.S. Food and Drug Administration (FDA) in 2014. This approval marked a major breakthrough in cancer treatment, leading to increased survival rates for patients with lung cancer, melanoma, and renal cell carcinoma. Additionally, Ono Pharmaceutical Co Ltd successfully expanded Opdivo's indications for other cancers such as bladder cancer and liver cancer in subsequent years. Furthermore, the company has formed strategic partnerships with international pharmaceutical companies, further strengthening its position in the global market.

Ono Pharmaceutical Co Ltd is a renowned pharmaceutical company based in Japan. Established in 1712, the company has a long-standing history in the healthcare industry. Ono Pharma focuses on the research, development, and manufacturing of innovative drugs and therapeutic solutions. With a strong commitment to improving global health, the company has made significant contributions to the field of oncology, immunology, and central nervous system disorders. Ono Pharma has collaborated with various international partners to expand its reach and enhance its product portfolio. Continuously striving for excellence, Ono Pharmaceutical Co Ltd has emerged as a trusted name in the pharmaceutical sector with its dedication to advancing medical science and improving patient outcomes.

The main competitors of Ono Pharmaceutical Co Ltd in the market include Takeda Pharmaceutical Co Ltd, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd, and Eisai Co Ltd.

Ono Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

The business model of Ono Pharmaceutical Co Ltd revolves around the research, development, manufacturing, and commercialization of innovative pharmaceutical products. As a leading Japanese pharmaceutical company, Ono focuses on the development of prescription drugs in various therapeutic areas, including oncology, immunology, and central nervous system disorders. Ono Pharmaceuticals' business model emphasizes a strong commitment to scientific excellence and collaboration with research institutions and other pharmaceutical companies. By continually investing in cutting-edge research and development, Ono aims to provide effective and safe medications to improve the quality of patients' lives globally.

مُعامل القيمة السوقية إلى الأرباح لـ Ono Pharmaceutical Co هو ٨٫٣٣.

مُعامِل القيمة إلى المبيعات Ono Pharmaceutical Co هو ٢٫١٢.

نقاط جودة AlleAktien لـ Ono Pharmaceutical Co هي 9/10.

Ono Pharmaceutical Co الإيرادات هي ٥٠٢٫٦٧ مليارات JPY.

صافي الربح Ono Pharmaceutical Co هو ١٢٧٫٩٨ مليارات JPY.

Ono Pharmaceutical Co. Ltd is a Japanese pharmaceutical company specializing in the development and distribution of innovative medications for over 70 years. It is headquartered in Osaka and focuses on multiple areas including oncology, immunology, neurology, and infectious diseases. In the field of oncology, Ono has established a leading position in the Asian market and offers a range of innovative treatment options for various types of cancer such as breast, lung, and prostate cancer. Some of their well-known products include Opdivo, an immunotherapy for treating different tumors, and Kyprolis, a medication for multiple myeloma. In the field of immunology, Ono focuses on developing treatments for autoimmune diseases and inflammation. This includes products such as Nivolumab for treating melanoma and renal cancer, Ozanimod for multiple sclerosis, and Etrolizumab for Crohn's disease and ulcerative colitis. Their neurology department encompasses medications for treating conditions like schizophrenia, depression, Parkinson's, and epilepsy. Well-known products in this area include antipsychotics like Olanzapine and Aripiprazole, as well as antiepileptics like Rufinamide and Gabapentin. Ono is also actively involved in developing therapies to combat infectious diseases. Some products in this area include Symbicort for asthma treatment and Dulera, an inhalable corticosteroid for seasonal and perennial allergic rhinitis. Ono's business model is based on continuous research and development of innovative medications that meet the needs of patients and doctors. The company continuously invests in research and development to meet the demands of the fast-paced pharmaceutical industry. Strategic partnerships with other pharmaceutical companies and university research departments also aim to expand their product range. In addition to product development, Ono also invests in improving its manufacturing processes and distribution channels. The company closely collaborates with distribution partners to market its products in Japan and internationally. Ono operates several subsidiary companies, including Ono Pharma USA Inc. and Ono Pharma UK Ltd., to distribute its products worldwide. The company aims to achieve a global reach and constantly expands its international network through partnerships with other companies and academic institutions. Overall, Ono Pharmaceutical Co. Ltd is a leading pharmaceutical company specializing in the development and marketing of innovative medications in various fields. With a strong presence in the Asian market and a growing international reach, Ono remains an important player in the pharmaceutical industry.

يوزع Ono Pharmaceutical Co أرباحًا قدرها ٦١٫٠٠ JPY من خلال 2 عمليات توزيع موزعة على مدار السنة.

Ono Pharmaceutical Co يوزع أرباحًا 2 مرة في السنة.

الرمز الدولي للأوراق المالية الخاص بـOno Pharmaceutical Co هو JP3197600004.

رمز WKN لـ Ono Pharmaceutical Co هو 859650.

الرمز المُختصر لـ Ono Pharmaceutical Co هو 4528.T.

خلال آخر 12 شهراً، دفعت Ono Pharmaceutical Co توزيعات أرباح بقيمة ٨٠٫٠٠ JPY . وهذا يعادل عائد توزيعات أرباح يقارب ٣٫٦٠ %. ومن المتوقع أن تدفع Ono Pharmaceutical Co خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ٨٦٫١٤ JPY.

نسبة توزيعات الأرباح الحالية لـ Ono Pharmaceutical Co هي ٣٫٦٠ %.

Ono Pharmaceutical Co يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر أكتوبر, أبريل, أكتوبر, أبريل.

Ono Pharmaceutical Co دفعت توزيعات الأرباح كل عام خلال الـ23 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة ٨٦٫١٤ JPY. وهذا يعادل عائد توزيعات أرباح قدره ٣٫٨٨ %.

Ono Pharmaceutical Co يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة ٤٠ JPY من Ono Pharmaceutical Co المُعلن عنها في ١‏/١٢‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٧‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١‏/١٢‏/٢٠٢٤.

في العام 2023، وزعت Ono Pharmaceutical Co ٧٧ JPY كأرباح أسهم.

يتم توزيع أرباح Ono Pharmaceutical Co بالعملة JPY.